gastrointestinal agent therapy proton pump inhibitor agent therapy 2019-01-22T20:38:35Z NCIT:C29723 proton pump inhibitor treatment therapy PPI agent therapy Any one of the substituted benzimidazole compounds with anti-ulcer activity. A proton pump inhibitor is orally administered in the neutrally charged, inactive form and, upon entering the acidic environment of the parietal cell, gets protonated and converted into its active form. The active form will covalently and irreversibly bind to the proton pump, the H+/K+-ATPase, located on the surface of parietal cells. This leads to an inhibition of the transport of hydrogen ions, in exchange for potassium ions, into the gastric lumen and results in an inhibition of gastric acid secretion. PPI treatment therapy proton pump inhibitor drug treatment PPI drug therapy